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The systemic inflammatory response, as evidenced by elevated circulating concentrations of C-reactive protein, is a stage-
independent prognostic factor in patients undergoing curative nephrectomy for localised renal cancer. However, it is not clear
whether the systemic inflammatory response arises from the tumour per se or as a result of an impaired immune cytokine response.
The aim of the present study was to examine C-reactive protein, interleukin-6 and interleukin-10 concentrations before and following
curative resection of renal cancer. Sixty-four patients with malignant renal disease and 12 with benign disease, undergoing resection
were studied. Preoperatively, a blood sample was collected for routine laboratory analysis with a further sample stored before
analysis of interleukin-6 and interleukin-10 using an enzyme-linked immunosorbent assay (ELISA) technique. The blood sampling
procedure and analyses were repeated at approximately 3 months following resection. Circulating concentrations of both interleukin-
6 and interleukin (Pp0.01) were higher and a greater proportion were elevated (Po0.05) in malignant compared with benign
disease. The renal cancer patients were grouped according to whether they had evidence of a systemic inflammatory response. In the
inflammatory group T stage was higher (Po0.01), both interleukin-6 and interleukin-10 concentrations were higher (Po0.001) and
elevated (Po0.10) compared with the non-inflammatory group. Tumour volume was weakly correlated with C-reactive protein
(r
2¼0.20, P¼0.002), interleukin-6 (r
2¼0.20, P¼0.002) and interleukin-10 (r
2¼0.24, P¼0.001). Following nephrectomy the
proportion of patients with elevated C-reactive protein, interleukin-6 and interleukin-10 concentrations did not alter significantly. An
elevated preoperative C-reactive protein was associated with increased tumour stage, interleukin-6 and interleukin-10
concentrations. However, resection of the primary tumour did not appear to be associated with significant normalisation of
circulating concentrations of C-reactive protein, interleukin-6 or interleukin-10. Therefore, the presence of systemic inflammatory
response is unlikely to be solely be determined by the tumour itself, but may be as a result of an impaired immune cytokine response
in patients with renal cancer.
British Journal of Cancer (2006) 95, 1076–1080. doi:10.1038/sj.bjc.6603387 www.bjcancer.com
Published online 26 September 2006
& 2006 Cancer Research UK
Keywords: renal cancer; nephrectomy; C-reactive protein; interleukin-6; interleukin-10; cancer-specific survival
                                                             
Renal cell cancer, although the 12th most common cause of cancer
death is one of the most lethal urological cancers. Each year in
the UK, there are approximately 3500 new cases and approxi-
mately 30% of patients present with metastases. Overall survival is
poor; even in those who undergo potentially curative resection,
only approximately half survive 5 years (Cancerstats, www.
cancerresearchuk.org).
It has recently become clear that the systemic inflammatory
response, as evidenced by elevated circulating concentrations of
C-reactive protein, is an important prognostic factor independent
of tumour stage in patients undergoing potentially curative surgery
for a number of solid tumours including colorectal (Nielsen et al,
2000; McMillan et al, 2003); gastro-oesophageal (Ikeda et al, 2003;
Crumley et al, 2006), pancreatic (Jamieson et al, 2005) and urinary
bladder (Hilmy et al, 2005) cancers.
It has also been shown that an elevated circulating C-reactive
protein concentration is associated with a poor prognosis in
patients with metastatic renal cancer (Atzpodien et al, 2003;
Bromwich et al, 2004; Casamassima et al, 2005). Furthermore,
an elevated C-reactive protein concentration has also been shown
to be associated with poor survival, independent of stage and
grade, in patients undergoing potentially curative resection for
renal cancer (Masuda et al, 1998; Lamb et al, 2006).
However, the basis of the independent relationship between an
elevated C-reactive protein concentration and poor survival in
renal cancer is not clear. Specifically, it is not clear whether the
systemic inflammatory response arises from the tumour per se or as
a result of an impaired immune cytokine response. Interleukin-6
and interleukin-10 are likely to be key cytokines in such a response
as they appear to have stimulant and suppressive actions,
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srespectively, on immune cells, in particular T-lymphocytes
(Gabay and Kushner, 1999; Jee et al, 2001; Trikha et al, 2003).
Interleukin-6 is recognised as an autocrine growth factor for
tumours, but also has a tumour suppressive role in promoting
anti-tumour activity of macrophages. (Trikha et al, 2003).
More recently, interleukin-10 has been recognised to be an
important immunosuppressive cytokine for the Th1 anti-tumour
response and may be important in determining tumour growth
and metastases (Mocellin et al, 2005).
The aim of the present study was to examine C-reactive protein,
interleukin-6 and interleukin-10 concentrations before and follow-
ing curative resection of renal cancer.
PATIENTS AND METHODS
Patients with benign and malignant renal disease, who underwent
resection between March 2003 and October 2005 in the North
Glasgow NHS Trust were included in the study. Patients were
staged pathologically according to the 1997 UICC TNM classifica-
tion of renal tumours (Sobin and Wittekind, 1997). Tumours
were graded according to criteria set out by Fuhrman et al (1982).
Clinical stage and performance status (Eastern Cooperative
Oncology Group, ECOG-ps) were recorded before surgery.
The Research Ethics Committee of North Glasgow NHS Trust
approved the study.
Experimental design
A blood sample was collected before resection for routine
laboratory analysis of haemoglobin, white cell count, percentage
lymphocyte count, albumin and C-reactive protein. The limit of
detection of the assay was a C-reactive protein concentration lower
than 6mgl
 1. The inter- and intra-assay variability of haemo-
globin, white cell count, albumin and C-reactive, protein were less
than 10%. A C-reactive protein concentration of greater than
10mgl
 1 was considered to indicate the presence of systemic
inflammatory response (O’Gorman et al, 2000; McMillan et al,
2001). A further blood sample taken before surgery was
centrifuged and the serum stored at  801C before analysis of
interleukin-6 and interleukin-10. Circulating concentrations of
these cytokines were measured using an enzyme-linked immuno-
sorbent assay (ELISA) technique. The minimum detectable
concentrations were 2pgml
 1 for interleukin-6 and 4pgml
 1 for
interleukin-10 (Quantikine ELISA, R&D Systems Europe Ltd,
Abingdon, UK). Inter- and intra-assay variability were less than
10% for both assays.
A second blood sample was obtained approximately 3 months
following nephrectomy for routine laboratory analysis and
cytokine quantification using the methods above.
Statistics
Data are presented as median and range. Comparisons between
groups of patients were carried out using contingency table
analysis (w
2) as appropriate. Cytokine concentrations below the
threshold of sensitivity of the respective assays were expressed
as equal to this threshold. Where appropriate, data were tested
for statistical significance using Mann–Whitney U test and the
Wilcoxon signed rank test. As the distribution of C-reactive
protein and the cytokines were skewed, they were logarithmically
transformed before stepwise multiple regression analysis for the
examination of independent associations with C-reactive protein.
Univariate survival analysis was performed using the Kaplan–
Meier method with the log-rank test. Deaths up to the end of
March 2006 were included in the analysis. Analysis was performed
using SPSS software (SPSS Inc., Chicago, IL, USA).
RESULTS
The clinicopathological characteristics of patients who underwent
resection for benign (n¼12) and malignant (n¼64) renal disease
are shown in Table 1. Age, sex, ECOG-ps, haemoglobin, white cell
count, percentage lymphocyte count, albumin and C-reactive
protein were similar in the two groups. Circulating concentrations
of both interleukin-6 and interleukin-10 (Pp0.01) were higher and
a greater proportion were elevated (Po0.05) in malignant
compared with benign disease.
The renal cancer patients were grouped according to whether
they had evidence of a systemic inflammatory response before
nephrectomy (C-reactive protein 410mgl
 1, Table 2). The groups
were similar in terms of age, sex, tumour volume, Fuhrman grade,
white cell count and percentage lymphocytes. In the inflammatory
group T stage was higher (Po0.01), number of cytoreductive
operations greater (Po0.05), both interleukin-6 and interleukin-10
concentrations were higher (Po0.001) and elevated (Po0.10)
compared with the non-inflammatory group. In contrast, haemo-
globin (Po0.01) and albumin (Po0.10) concentrations and
ECOG-ps (Po0.05) were lower in the inflammatory group.
Tumour volume was correlated with C-reactive protein
(r
2¼0.20, P¼0.002), interleukin-6 (r
2¼0.20, P¼0.002) and
interleukin-10 (r
2¼0.24, P¼0.001).
The minimum follow-up was 7 months or until date of death; the
median follow-up of the survivors was 25 months. During this
period, 15 (20%) patients died: 11 patients of their cancer and four
of intercurrent disease. On univariate analysis, an elevated C-
reactive protein concentration before resection was associated with
reduction in cancer-specific survival (P¼0.014).
In the cancer patients who had detectable circulating preopera-
tive C-reactive protein concentrations (n¼41), log-transformed
concentrations of C-reactive protein were significantly correlated
with interleukin-6 (r
2¼0.62, Po0.001, Figure 1A) and interleukin-
10 (r
2¼0.33, Po0.001, Figure 1B). On multiple regression analysis
of both interleukin-6 and interleukin-10 on C-reactive protein,
only interleukin-6 (r
2¼0.63, Po0.001) retained independent
significance. Interleukin-6 was significantly correlated with IL-10
(r
2¼0.49, Po0.001).
The clinicopathological characteristics of the patients who
had undergone a potentially curative operation, before and
approximately 3 months following nephrectomy, are shown in
Table 1 Clinicopathological characteristics in patients with benign and
malignant renal disease before nephrectomy
Benign
disease
(n¼12)
Renal cancer
(n¼64) P-value
Age group (p60/460 years) 9/3 35/29 0.194
Sex (male/female) 4/8 42/22 0.037
T stage (1/2/3/4) 27/4/21/12
Tumour volume (cm
3) 112 (1–4864)
Fuhrman grade (1/2/3/4) 8/16/21/13
Operation (curative/cytoreductive) 54/10
ECOG-PS (0/1) 12/0 53/11 0.123
Haemoglobin (X12/o12gdl
 1) 9/3 50/14 0.813
White cell count
(o8.5/8.5–11.0/411.0 10
9l
 1) 7/5/0 48/13/3 0.486
Lymphocyte percentage
(20–40/12.0–19.9/0–11.9%) 10/2/0 43/15/6 0.199
Albumin (X35/o35gl
 1) 11/0 59/3 0.459
C-reactive protein (p10/410mgl
 1) 8/4 34/30 0.390
Interleukin-6 (pgml
 1) o2( o2–19) 4 (o2–142) 0.007
Interleukin-6 (p4/44pgml
 1) 10/1 33/31 0.015
Interleukin-10 (pgml
 1) o4( o4–7) 6 (o4–66) 0.012
Interleukin-10 (p10/410pgml
 1) 12/0 45/19 0.030
ECOG, Eastern Cooperative Oncology Group. Median (range).
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lymphocyte count, albumin and an elevated C-reactive protein
concentration did not change significantly over this period. In
contrast, there was a fall in performance status (Po0.01),
haemoglobin (Po0.01) and an increase in white cell count during
this period. Changes in interleukin-6 and interleukin-10 concen-
trations did not reach statistical significance.
In the cancer patients who had detectable circulating post-
operative C-reactive protein concentrations (n¼35), log-trans-
formed concentrations of C-reactive protein were significantly
correlated with those of interleukin-6 (r
2¼0.66, Po0.001) and
interleukin-10 (r
2¼0.33, Po0.001). On multiple regression
analysis of both interleukin-6 and interleukin-10 on C-reactive
protein, only interleukin-6 (r
2¼0.66, Po0.001) retained indepen-
dent significance. Interleukin-6 was significantly correlated with
interleukin-10 (r
2¼0.51, Po0.001).
DISCUSSION
In the present study, both interleukin-6 and interleukin-10
concentrations were greater in malignant compared with benign
renal disease. Furthermore, both were directly associated with C-
reactive protein and did not appear to normalise on resection of
the primary renal tumour.
These results appear to contradict the report of Ljungberg
et al (1995) who, in a similar study design of 56 patients with
stage I renal cancer reported that a number of acute phase
proteins including C-reactive protein fell significantly
approximately 6 months after resection. However, in the
present study, when the analysis was confined to those patients
with stage I disease, neither C-reactive protein, interleukin-6 or
interleukin-10 appeared to normalise on resection of the primary
tumour.
Galizia et al (2002) in a similar study design in 50 patients
with colon reported that that both interleukin-6 and interleukin-10
concentrations fell by day 16 following resection. However, it
was of interest that, in their study, the median concentrations
of interleukin-6 and interleukin-10, before surgery, were higher
(8 and 15pgml
 1, respectively) compared with the results (3 and
5pgml
 1, respectively) in the present study. Nevertheless,
consistent with the present study Galizia et al (2002) observed
that the majority of patients did not normalise their cytokine
concentrations following radical resection.
Table 2 Clinicopathological characteristics of inflammatory and non-inflammatory patients with renal cancer before nephrectomy
C-reactive protein p10mgl
 1
(n¼34) median o6mgl
 1
C-reactive protein410mgl
 1
(n¼30) median 35mgl
 1 P-value
Age group (p60/460 years) 17/17 18/12 0.426
Sex (male/female) 23/11 19/11 0.719
T stage (1/2/3/4) 19/2/11/2 8/2/10/10 0.005
Tumour volume (cm
3) 64 (1–1331) 179 (9–4864) 0.123
Fuhrman grade (1/2/3/4) 5/11/9/6 3/5/12/7 0.193
Operation (curative/cytoreductive) 32/2 22/8 0.023
ECOG-PS (0/1) 32/2 21/9 0.011
Haemoglobin (X12/o12gdl
 1) 31/3 19/11 0.008
White cell count
(o8.5/8.5–11.0/411.0 10
9l
 1) 26/8/0 22/5/3 0.344
Lymphocyte percentage
(20–40/12.0–19.9/0–11.9%) 26/6/2 17/9/4 0.100
Albumin (X35/o35gl
 1) 33/0 26/3 0.060
Interleukin-6 (pgml
 1) o2( o2–20) 16 (o2–142) 0.001
Interleukin-6 (p4/44pgml
 1) 22/12 11/19 0.026
Interleukin-10 (pgml
 1) o4( o4–66) 8 (o4–35) 0.013
Interleukin-10 (p10/410pgml
 1) 27/7 18/12 0.092
Cancer–specific survival (months)
a 34.8 (32.6–37.1) 28.1 (23.1–33.0) 0.014
ECOG, Eastern Cooperative Oncology Group. Median (range).
aMean (95%CI).
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Figure 1 (A) Relationship between circulating concentrations of
interleukin-6 and C-reactive protein in patients with renal cancer.
(B) Relationship between circulating concentrations of interleukin-10 and
C-reactive protein in patients with renal cancer.
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studies is not clear. Nevertheless, the results of the present study
are consistent with previous pre-/postoperative C-reactive protein
findings in colorectal, pancreatic and bladder cancer (McMillan
et al, 2003; Jamieson et al, 2005; Hilmy et al, 2005). Furthermore, if
there were to be a significant conversion rate from a systemic
inflammatory state (C-reactive protein 410mgl
 1) to a non-
inflammatory state (C-reactive protein p10mgl
 1) following
resection then the prognostic value of markers of the systemic
inflammatory response would be significantly degraded.
The elevated circulating concentrations of interleukin-6 and
interleukin-10 following resection of renal cancer may reflect a
continuing Th2 cytokine response as increased intra-tumoural
CD4þ T-lymphocyte infiltrate has been shown to be associated
with poor outcome, independent of grade, in patients with renal
clear-cell cancer (Bromwich et al, 2003). This would be consistent
with the observations in the present study that circulating
interleukin-6 and interleukin-10 concentrations were not strongly
correlated with tumour volume but were similarly correlated with
each other before and after resection of the renal tumour.
Moderation of this cytokine response may be important in the
regulation of the systemic inflammatory response and warrants
further clinical investigation.
Given the considerable variability of the effect of resection on
C-reactive protein, interleukin-6 and interleukin-10 seen in the
present study it would require a much larger study to absolutely
preclude the possibility that surgical resection of renal cancer does
not reduce C-reactive protein, interleukin-6 and interleukin-10
concentrations. Nevertheless, the results of the present study
would suggest that the presence of systemic inflammatory
response is not solely determined by the elaboration of cytokines
from the tumour.
In summary, an elevated preoperative C-reactive protein was
associated with increased tumour stage, interleukin-6 and inter-
leukin-10 concentrations. However, resection of the primary
tumour did not appear to be associated with significant normal-
isation of circulating concentrations of C-reactive protein, inter-
leukin-6 or interleukin-10. Therefore, the presence of systemic
inflammatory response is unlikely to be solely be determined by
the tumour itself, but may be as a result of an impaired immune
cytokine response in patients with renal cancer.
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